Home » Stocks » ANCN

Anchiano Therapeutics Ltd. (ANCN)

Stock Price: $2.31 USD 0.22 (10.53%)
Updated Jan 20, 2021 1:28 PM EST - Market open
Market Cap 15.51M
Revenue (ttm) n/a
Net Income (ttm) -414,000
Shares Out 37.10M
EPS (ttm) -2.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $2.31
Previous Close $2.09
Change ($) 0.22
Change (%) 10.53%
Day's Open 2.11
Day's Range 2.02 - 2.44
Day's Volume 467,826
52-Week Range 0.60 - 2.62


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 3 weeks ago

NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Anchiano Therapeutics Ltd. (NASDAQ: ANCN) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with th...

PRNewsWire - 1 month ago

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. ("...

InvestorPlace - 1 month ago

Anchiano Therapeutics (ANCN) stock is soaring higher on Tuesday following news of a merger with Chemomab that will bring major changes. The post ANCN Stock: Why Anchiano Therapeutics Stock Is ...

GuruFocus - 1 month ago

As of Dec. 10, the GuruFocus All-in-One Screener, a Premium feature, found that the following health care companies have low price-earnings ratios and are owned by gurus. While some of them ar...

Other stocks mentioned: HAPP, TMDI, YCBD, ZCMD
Zacks Investment Research - 3 months ago

Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Com...

About ANCN

Anchiano Therapeutics, a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration... [Read more...]

IPO Date
Feb 12, 2019
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements